|
rs1130409
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no evidence to suggest that rs25489, rs1799782, rs1130409, rs1805414 and rs1136410 were associated with breast cancer risk.
|
29662639 |
2018 |
|
rs1130409
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A total of 518 patients with histopathologically confirmed breast cancer and 921 region- and age-matched cancer-free controls were genotyped for the APEX1 polymorphisms rs3136817 and rs1130409 and the OGG1 polymorphisms rs1052133 and rs2072668 using a QuantStudio™ 12 K Flex Real-Time PCR System.
|
29720094 |
2018 |
|
rs1130409
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Taken together, this is the first report that established that Asp148Glu variant has structural and functional effect on the APE1 and may play an important role in breast cancer progression in Saudi population.
|
26257461 |
2015 |
|
rs1130409
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We observed two two-way SNP-SNP interactions (APEX1-rs1130409 and RPAP1-rs2297381; MLH1-rs1799977 and MDM2-rs769412) in logistic regression that conferred elevated risks for breast cancer (P(interaction)<7.3 × 10(-3)).
|
23755158 |
2014 |
|
rs1130409
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis suggested that the APE1 Asp148Glu polymorphism was a risk factor for breast cancer susceptibility among Asian population.
|
24414702 |
2014 |
|
rs1130409
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Single nucleotide polymorphisms (SNPs) of OGG1 (Ser326Cys), XRCC1 (Arg399Gln), and APE1 (Asp148Glu and -141T/G) were genotyped and analyzed for their association with breast cancer risk using multivariate logistic regression models.
|
24606430 |
2014 |
|
rs1130409
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
With respect to APE1 Asp148Glu polymorphism, no significant association with breast cancer risk was demonstrated in the overall and stratified analyses.
|
24893568 |
2014 |
|
rs1130409
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The APEX1 Asp148Glu carrier, in combination with OGG1 rs2072668 and OGG1 Ser326Cys, was strongly associated with an increased risk of BC.
|
24076439 |
2013 |
|
rs1130409
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis indicates that ADPRT Val762Ala and APE1 Asp148Glu polymorphisms are not associated with increased breast cancer risk.
|
23272074 |
2012 |
|
rs1130409
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Statistically significant association with breast cancer</span> risk was observed for rs1130409 homozygous mutant GG [odds ratio (OR) 3.35, 95% confidence interval (CI) 1.36-8.26), heterozygous GT (OR 2.42, 95% CI 1.56-3.76), and combined mutant (GT + GG) (OR 2.52, 95% CI 1.65-3.86] genotypes and rs25487 homozygous mutant AA (OR 2.91, 95% CI 1.66-5.10) and combined mutant (AA + AG) (OR 1.41, 95% CI 0.903-2.19) genotypes, whereas protective association was exhibited by rs1799782 homozygous mutant CC (OR 0.413, 95% CI 0.082-2.08), heterozygous TC (OR 0.351, 95% CI 0.189-0.650), and combined mutant (TC + CC) (OR 0.357, 95% CI 0.199-0.641) genotypes.
|
18669164 |
2008 |
|
rs1130409
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using data/samples collected from the first 752 Caucasians and 141 African-Americans in an ongoing case-control study, we examined the association between breast cancer risk and 18 non-synonymous single-nucleotide polymorphisms (nsSNPs) in four DNA repair pathways-(i) base excision repair: ADPRT V762A, APE1 D148E, XRCC1 R194W/R280H/R399Q and POLD1 R119H; (ii) nucleotide excision repair: ERCC2 D312N/K751Q, ERCC4 R415Q, ERCC5 D1104H and XPC A499V/K939Q; (iii) mismatch repair: MLH1 I219V, MSH3 R940Q/T1036A and MSH6 G39E and (iv) double-strand break repair: NBS1 E185Q and XRCC3 T241M.
|
18701435 |
2008 |
|
rs1130409
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Previous association studies of breast cancer and BRCA2 N372H and functional observations for APEX D148E ran counter to our findings of decreased risks.
|
15113441 |
2004 |